-
In April 2026, COMPASS Pathways announced that the FDA granted a rolling NDA review for its synthetic psilocybin therapy COMP360 in treatment-resistant depression and selected it for the Commissioner’s National Priority Voucher program, following positive Phase 3 data in more than 1,000 participants.
-
This makes COMP360 the first classic psychedelic to show highly statistically significant, clinically meaningful Phase 3 results in treatment-resistant depression with rapid onset, multi‑month durability, and a generally well-tolerated safety profile, potentially reshaping expectations for how quickly and effectively severe depression may be treated.
-
We’ll now examine how the rolling NDA review and priority voucher for COMP360 could reshape COMPASS Pathways’ investment narrative and outlook.
We’ve uncovered the 13 dividend fortresses yielding 5%+ that don’t just survive market storms, but thrive in them.
COMPASS Pathways Investment Narrative Recap
To own COMPASS Pathways, you need to believe COMP360 can convert strong Phase 3 data and regulatory momentum into an approved, widely used treatment for severe depression. The rolling NDA review and National Priority Voucher sharpen the focus on FDA approval timing as the key near term catalyst, while the company’s ongoing cash burn and pre revenue status keep financing and dilution risk front and center. At this stage, the new FDA actions appear to strengthen, rather than change, that core setup.
The collaboration with Osmind is especially relevant here, because it speaks to how COMP360 could be delivered if approved. By working with a network of more than 1,000 interventional psychiatry clinics, COMPASS is gathering real world insight into operational and infrastructure needs, which ties directly into future launch execution and the company’s ability to translate any regulatory success for COMP360 into actual treatment volumes and, eventually, commercial returns.
Yet despite the FDA momentum, investors should also be aware that the company’s ongoing losses and potential need for more capital could still…
Read the full narrative on COMPASS Pathways (it’s free!)
COMPASS Pathways’ narrative projects $193.1 million revenue and $24.2 million earnings by 2029. This requires revenue to grow from zero to $193.1 million by that year and an earnings increase of about $261.5 million from -$237.3 million today.
Uncover how COMPASS Pathways’ forecasts yield a $21.92 fair value, a 143% upside to its current price.
Exploring Other Perspectives 
CMPS 1-Year Stock Price Chart
Before this FDA news, the most optimistic analysts were already penciling in about US$670.7 million of revenue and US$242.9 million of earnings by 2029, so if you see the voucher and rolling review as easing regulatory risk more than consensus assumes, you may lean closer to that upbeat view, while also questioning whether those forecasts and the expectation of faster approval…
Explore 5 other fair value estimates on COMPASS Pathways – why the stock might be worth just $13.53!
Form Your Own Verdict
Don’t just follow the ticker – dig into the data and build a conviction that’s truly your own.
Ready For A Different Approach?
Markets shift fast. These stocks won’t stay hidden for long. Get the list while it matters:
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Companies discussed in this article include CMPS.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com